Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor
| Autor: | Takashi, Sato, Kiyoshi, Takagi, Mitsunori, Higuchi, Hiroko, Abe, Michie, Kojimahara, Miho, Sagawa, Megumi, Tanaki, Yasuhiro, Miki, Takashi, Suzuki, Hiroshi, Hojo |
|---|---|
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | ACTA HISTOCHEMICA ET CYTOCHEMICA. 55:25-35 |
| ISSN: | 1347-5800 0044-5991 |
| DOI: | 10.1267/ahc.21-00075 |
| Popis: | It has been demonstrated that tumor cells express programed cell death protein 1 (PD-L1) to escape T lymphocytes that express programed cell protein 1 (PD-1), and PD-1/PD-L1 immune checkpoint inhibitors have been regarded in lung cancer patients. CD80 and CD86 are members of B7 superfamily which regulates T lymphocyte activation and tolerance. However, immunolocalization of CD80 and CD86 has not been examined in the lung carcinoma tissues and their clinical significance remains unknown. Therefore, to clarify clinical significance of CD80 and CD86, we immunolocalized these in 75 non-small cell lung carcinomas (NSCLC) in this study. Immunoreactivities of CD80 and CD86 were mainly detected in tumor-infiltrating macrophages. Immunohistochemical CD80 status was high in 56% of NSCLC, and it was positively associated with stage, pathological T factor, distant metastasis, histological type and PD-L1 status. Moreover, multivariate analysis turned out that the CD80 status was an independent worse prognostic factor. CD86 status was high in 53% of the cases, but it was not significantly associated with any clinicopathological parameters. These findings suggest that CD80 is a potent worse prognostic factor possibly in association with escape from immune attack in NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|